CLAIMS

1. A composition comprising: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an ATTIIR2 antagonist; or, an ACEi, a beta-blocker, and an ATIIR2 antagonist; wherein the composition is suitable for local administration.

2. A composition according to claim 1, which is suitable for, and is for, treating hemangioma.

3. A composition as claimed in claim 1 or 2, wherein the composition is suitable for, and is for, topical administration.

4. A composition as claimed in claim 1, 2 or 3, wherein the composition comprises two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists.

5. A composition as claimed in any one of the preceding claims, wherein the composition comprises a lower amount of beta-blocker relative to the amount of ACEi.

6. A composition as claimed in any one of the preceding claims, wherein the ACEi is a prodrug.

7. A composition as claimed in any one of the preceding claims, wherein the ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, trandolapril, Quinapril, Benazepril, and Captopril.

8. A composition as claimed in any one of the preceding claims, wherein the beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.

9. A composition as claimed in any one of the preceding claims, wherein the beta-blocker is a non-selective beta-blocker.

10. A composition as claimed in any one of the preceding claims, wherein the beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S-Timolol.

11. A composition as claimed in any one ofthe preceding claims, wherein the ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.

12. A composition as claimed in any one of the preceding claims, wherein the composition comprises: Cilazapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril and b) S-propranolol or racemic (R/S) propranolol; a) Ramipril or enalapril or trandolapril and b) S-propranolol or racemic (R/S) propranolol; Cilazapril and timolol; a) Ramipril or enalapril or trandolapril and b) timolol; a) L-159,686 or EMA401 and b) R-propranolol; a) L-159,686 or EMA401 and b) S-propranolol or racemic propranolol; a) L-159,686 or EMA401 and b) timolol; a) L-159,686 or EMA401 and b) cilazapril; or, a) L-159,686 or EMA401 and b) Ramipril or enalapril or trandolapril.

13. A composition as claimed in any one of the preceding claims, wherein the composition comprises: R-timolol and cilazapril; S-timolol and cilazapril; R/S-timolol and cilazapril; R-propranolol and cilazapril; S-propranolol and cilazapril; R/S-propranolol and cilazapril; L-159,686 and cilazapril; R-propranolol and L-159,686; S-propranolol and L-159,686; R/S-propranolol and L-159,686; L-159,686 and S-timolol; L-159,686 and R-timolol; EMA401 and S-timolol; EMA401 and R-timolol; EMA401 and cilazapril; EMA401 and R-propranolol; EMA401 and S-propranolol; or, EMA401 and R/S-propranolol.

14. A composition as claimed in any one of claims 33 to 44, wherein the composition comprises: a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-selective beta-blocker and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in prodrug form.

15. The use of an ACEi and a beta-blocker in the manufacture of a composition for the treatment of hemangioma, preferably by local administration.